Skip to content
2000
Volume 20, Issue 18
  • ISSN: 0929-8673
  • E-ISSN: 1875-533X

Abstract

Arundic acid has been experimented in vitro and in vivo as a potential neuroprotective agent. It modulates astrocyte activation by inhibiting the enhanced astrocytic synthesis of S-100β protein, responsible for inducing neuronal death. The phase II clinical trials for the treatment of acute ischemic stroke, as well as clinical development in other neurodegenerative diseases including amytrophic lateral sclerosis, Alzheimer's disease and Parkinson's disease are recently completed. There is no review published in this area since its discovery as potential neuroprotective agent and the various syntheses reported for this important non-natural compound. This review summarizes the studies towards the development of arundic acid as a neuroprotective agent, the biological studies in vitro and in vivo, the phase II trials and the various efforts made for its synthesis in the last two decades.

Loading

Article metrics loading...

/content/journals/cmc/10.2174/0929867311320180003
2013-06-01
2025-05-02
Loading full text...

Full text loading...

/content/journals/cmc/10.2174/0929867311320180003
Loading
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test